Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4911 - Impact of haptoglobin polymorphism on survival of renal cell carcinoma patients


10 Sep 2017


Poster display session


Translational Research;  Renal Cell Cancer


Tijl Vermassen


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


T. Vermassen1, N. Lumen2, J. Delanghe3, S. Rottey1

Author affiliations

  • 1 Department Medical Oncology, Ghent University Hospital, 9000 - Ghent/BE
  • 2 Department Urology, Ghent University Hospital, 9000 - Ghent/BE
  • 3 Department Clinical Chemistry, Ghent University Hospital, 9000 - Ghent/BE


Abstract 4911


Renal cell carcinoma (RCC) accounts for 2.4% of all malignancies worldwide with 338,000 estimated new cases globally in 2012. With 144,000 deaths annually, RCC is the 16th cancer-related death worldwide. In the last decade, the use of targeted therapy for patients with metastatic RCC has increased exponentially, especially since the breakthroughs with cabozantinib and nivolumab. Apart from the Heng criteria in 1st-line therapy, no robust biochemical markers exist for the prognosis of RCC patients. Here we assessed the prognostic value of haptoglobin (Hp) polymorphisms on survival of RCC patients.


At interim analysis, 53 metastatic RCC patients were enrolled and Hp phenotypes were determined prospectively. Survival data was retrieved from the electronic patient files. Kaplan-Meier survival analyses were performed for disease-free survival (DFS), progression-free survival (PFS) after 1st- and 2nd-line therapy, and overall survival (OS).


Fifty-eight percent of patients were male. Hp distribution was 19%, 49% and 32% for Hp 1-1, 2-1 and 2- phenotypes, respectively. Median follow-up since development of metastatic disease was 4.7 years (95% CI 3.3 – 6.5). Lowest DFS was found in patients with Hp 2-2 phenotypes. This was significant when Hp 2-2 phenotypes were compared with Hp 1-1/2-1 phenotypes (hazard ratio [HR] = 1.93 [95%CI 1.12 – 5.75], P = 0.0255). No significant difference between Hp phenotypes was noticed for PFS after 1st-line therapy. After 2nd-line therapy, longest PFS was observed in patients with Hp 2-1 and 2-2 phenotypes which was better compared with Hp 1-1 phenotypes. Lastly, OS was found to be longer in patients with Hp 2-1 and 2-2 phenotypes, although no significance was observed versus patients with Hp 1-1 phenotypes. Median durations of survival and HRs versus Hp 1-1 phenotypes are given in Table.Table:

906P Hp survival analysis

CohortHpNMedian survivalHR vs Hp 1-1P-value
DFS (years)1-190.6 (0.2 – 4.3)10.0616
2-1192.3 (0.6 – 5.0)0.73 (0.34 – 1.59)
2-2140.5 (0.1 – 0.9)1.54 (0.60 – 3.97)
PFS 1st-line (months)1-1911.7 (2.4 – 17.6)10.7529
2-12614.7 (6.5 – 28.7)0.90 (0.33 – 2.45)
2-2176.7 (4.2 – 52.2)1.20 (0.40 – 3.54)
PFS 2nd-line (months)1-153.2 (0.9 – 3.9)10.0001
2-1166.2 (5.4 – 17.6)0.21 (0.03 – 0.87)
2-21216.4 (6.9 – 27.6)0.13 (0.02 – 0.67)
OS (years)1-1101.7 (1.2 – 2.7)10.4205
2-1263.8 (2.3 – 6.2)0.56 (0.20 – 1.60)
2-2173.5 (1.6 – 7.1)0.61 (0.20 – 1.87)


Interim analysis shows that Hp phenotype has prognostic potential, especially in DFS and PFS during 2nd-line therapy. Continuation of the research on this topic is warranted.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Ghent University


Ghent University


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.